StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.37−0.39 (-5.03%)

Close on Nov 16, 2026Market cap $395.25MP/E –Yield –

Avalo Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Avalo Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -123601.7%. For fiscal 2025 it was -123601.7%, against -15535.6% the year before. The highest annual figure on record is 49.9% in fiscal 2017.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-123601.7%−108066.1
FY2024Dec 31, 2024-15535.6%−14114.0
FY2023Dec 31, 2023-1421.6%−1214.2
FY2022Dec 31, 2022-207.4%+1314.2
FY2021Dec 31, 2021-1521.6%−434.2
FY2020Dec 31, 2020-1087.4%−848.3
FY2019Dec 31, 2019-239.1%+264.3
FY2018Dec 31, 2018-503.4%−553.3
FY2017Dec 31, 201749.9%+1444.6
FY2016Dec 31, 2016-1394.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-33461.0%−31872.0
Q4 FY2024Dec 31, 2024-6932.8%−5820.8
Q3 FY2024Sep 30, 2024-5165.1%−3314.1
Q4 FY2023Dec 31, 2023-1341.2%−352.9
Q3 FY2023Sep 30, 2023-1589.0%−1616.4
Q2 FY2023Jun 30, 2023-1112.0%+33.0
Q1 FY2023Mar 31, 2023-1850.9%−73.2
Q4 FY2022Dec 31, 2022-988.3%+7214.0
Q3 FY2022Sep 30, 202227.4%+1246.9
Q2 FY2022Jun 30, 2022-1145.0%−634.5
Q1 FY2022Mar 31, 2022-1777.7%+4687.4
Q4 FY2021Dec 31, 2021-8202.3%−7110.8
Q3 FY2021Sep 30, 2021-1219.5%−24.4
Q2 FY2021Jun 30, 2021-510.6%+372.5
Q1 FY2021Mar 31, 2021-6465.1%−5324.5
Q4 FY2020Dec 31, 2020-1091.4%−106.1
Q3 FY2020Sep 30, 2020-1195.0%−1065.1
Q2 FY2020Jun 30, 2020-883.0%−700.0
Q1 FY2020Mar 31, 2020-1140.6%−946.4
Q4 FY2019Dec 31, 2019-985.3%−954.1
Q3 FY2019Sep 30, 2019-130.0%+466.7
Q2 FY2019Jun 30, 2019-183.1%−62.8
Q1 FY2019Mar 31, 2019-194.3%−110.5
Q4 FY2018Dec 31, 2018-31.3%+196.7
Q3 FY2018Sep 30, 2018-596.7%−684.2
Q2 FY2018Jun 30, 2018-120.2%+1004.6
Q1 FY2018Mar 31, 2018-83.8%+410.5
Q4 FY2017Dec 31, 2017-228.0%+703.7
Q3 FY2017Sep 30, 201787.6%+1942.4
Q2 FY2017Jun 30, 2017-1124.8%–
Q1 FY2017Mar 31, 2017-494.3%–
Q4 FY2016Dec 31, 2016-931.7%–
Q3 FY2016Sep 30, 2016-1854.9%–

More Avalo Therapeutics figures

See a number that looks wrong?